ReviewCurrent heart failure reports2022
Sarcopenia and Frailty in Heart Failure: Is There a Biomarker Signature?
Review in Current heart failure reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Handgrip strength and the prognosis of patients with heart failure: A meta-analysis.Clinical cardiology · 2023Pooled it
- Premorbid sarcopenia and functional outcome after acute stroke: a meta-analysis.Asia Pacific journal of clinical nutrition · 2023Pooled it
- Evaluating procollagen type III N-terminal propeptide (P3NP) as a biomarker of sarcopenia in women with type 2 diabetes: a cross-sectional study.Archives of endocrinology and metabolism · 2026Article
- Myokines in exercise‑mediated bone homeostasis: Molecular signaling mechanisms and therapeutic implications for bone disorders (Review).International journal of molecular medicine · 2026Review
- Joint analysis of hemoglobin-to-RDW and creatinine-to-albumin ratios for mortality prediction in critical heart failure.iScience · 2026Article
- Muscle Strength and Left Ventricular Systolic and Diastolic Dysfunction in Chronic Kidney Disease Men: A Pilot Study.Journal of clinical medicine · 2026Article
- Frailty identifies early and non-cardiac healthcare utilization after cardiovascular hospitalization.Frontiers in cardiovascular medicine · 2026Article
- Cardiovascular remodeling: key mechanisms and clinical implications linking sarcopenia and heart failure.Frontiers in medicine · 2026Review
- Sarcopenia in atrial fibrillation: a prospective study.Turkish journal of medical sciences · 2026Article
- Prognostic role of sarcopenia in heart failure patients.Cardiovascular diabetology · 2025Article
- Knockdown of CLEC4D alleviates myoblast dysfunction and inflammation in sarcopenia by inhibiting the JAK/STAT pathway.BMC musculoskeletal disorders · 2025Article
- Do weight loss interventions challenge the obesity paradox in heart failure?Trends in endocrinology and metabolism: TEM · 2025Article
- Heart Failure With Preserved Ejection Fraction and Frailty: From Young to Superaged Coexisting HFpEF and Frailty.International journal of heart failure · 2024Review
- Impact of Low-Density Lipoprotein Cholesterol Levels at Acute Coronary Syndrome Admission on Long-Term Clinical Outcomes.Journal of atherosclerosis and thrombosis · 2024Article
- Relationship of Low Vitamin B6 Status with Sarcopenia, Frailty, and Mortality: A Narrative Review.Nutrients · 2024Review
- Age-related outcomes in patients with cardiogenic shock stratified by etiology.Journal of geriatric cardiology : JGC · 2023Article
- Circulating H-FABP as a biomarker of frailty in patients with chronic heart failure.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Association between changes in predicted body composition and occurrence of heart failure: a nationwide population study.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewSarcopenia and frailty are common in patients with heart failure (HF) and are strongly associated with prognosis. This review aims to examine promising biomarkers that can guide physicians in identifying sarcopenia and frailty in HF. RECENT
findingsTraditional biomarkers including C-reactive protein, aminotransaminase, myostatin, and urinary creatinine as well as novel biomarkers including microRNAs, suppression of tumorigenicity 2 (ST2), galectin-3, and procollagen type III N-terminal peptide may help in predicting the development of sarcopenia and frailty in HF patients. Among those biomarkers, aminotransferase, urinary creatinine, and ST2 predicted the prognosis in HF patients with sarcopenia and frailty. This review outlines the current knowledge of biomarkers that are considered promising for diagnosing sarcopenia and frailty in HF. The listed biomarkers might support the diagnosis, prognosis, and therapeutic decisions for sarcopenia and frailty in HF patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.